Tenet Healthcare (THC) Expected to Post Earnings on Friday

Tenet Healthcare (NYSE:THC) is anticipated to announce its Q2 2026 results before the market opens on Friday, July 24th. Analysts expect the company to post earnings of $4.26 per share and revenue of $5.4316 billion for the quarter. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, July 24, 2026 at 11:30 AM ET.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, beating the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The business had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.39 billion. During the same quarter in the previous year, the business earned $4.36 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. On average, analysts expect Tenet Healthcare to post $18 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Tenet Healthcare Trading Down 0.3%

Shares of NYSE:THC opened at $195.84 on Thursday. The company has a quick ratio of 1.30, a current ratio of 1.36 and a debt-to-equity ratio of 1.96. Tenet Healthcare has a 52-week low of $146.60 and a 52-week high of $247.21. The stock has a market cap of $16.87 billion, a price-to-earnings ratio of 10.18, a PEG ratio of 1.63 and a beta of 1.27. The business has a 50-day moving average price of $184.41 and a 200-day moving average price of $197.37.

Wall Street Analysts Forecast Growth

THC has been the subject of a number of recent research reports. KeyCorp reduced their price target on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Barclays raised their target price on shares of Tenet Healthcare from $238.00 to $240.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. TD Cowen decreased their target price on shares of Tenet Healthcare from $242.00 to $233.00 and set a “buy” rating for the company in a research report on Monday, June 22nd. Guggenheim cut their price target on Tenet Healthcare from $252.00 to $242.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Royal Bank Of Canada reduced their price objective on Tenet Healthcare from $277.00 to $236.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Seventeen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $244.84.

Insider Buying and Selling at Tenet Healthcare

In related news, Director Nadja West sold 3,000 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total transaction of $532,050.00. Following the sale, the director directly owned 24,805 shares of the company’s stock, valued at approximately $4,399,166.75. This represents a 10.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the completion of the transaction, the director directly owned 16,804 shares of the company’s stock, valued at $2,932,634.08. The trade was a 25.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.97% of the company’s stock.

Institutional Trading of Tenet Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in THC. Triumph Capital Management acquired a new stake in Tenet Healthcare in the 3rd quarter valued at $25,000. Canada Pension Plan Investment Board purchased a new stake in shares of Tenet Healthcare during the second quarter worth about $35,000. Meeder Asset Management Inc. raised its position in shares of Tenet Healthcare by 146.2% during the 4th quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock worth $38,000 after purchasing an additional 114 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in Tenet Healthcare by 50.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock valued at $46,000 after buying an additional 89 shares in the last quarter. Finally, Wilkerson Advisory Group LLC acquired a new stake in Tenet Healthcare in the 4th quarter worth about $62,000. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.